Live
- Delhi HC dismisses anticipatory bail plea of ex-IAS trainee officer Puja Khedkar
- Untouched Goa Beaches You Must Visit in January
- Muzigal launches its State-of-the-art Music Academy in Nallagandla, Hyderabad
- Thoughtful Christmas Gifts for Every Loved One
- South Korea: Finance minister silent on martial law probe amid speculation on acting president's role
- Karnataka Minister Laxmi Hebbalkar Vows To Pursue Justice Against CT Ravi
- Stands By Vijayaraghavan Amid Row Over Remarks On Gandhis
- Karnataka Legislative Council Chairman Denies Recording Controversial Exchange
- Lexus India to Redefine Luxury Mobility at Bharat Mobility Global Expo 2025
- Hindustan Zinc Supported Farmers Achieve INR 5 Cr Revenue Through Five Farmer Produce Organizations
5 pharma companies team up on clinical trials
5 pharma companies team up on clinical trials
Dr Reddy’s, Cipla, Emcure Pharma, Sun Pharma and Torrent will collaborate for clinical trial of the investigational oral antiviral drug Molnupiravir during June-Sept across India
New Delhi: Leading drug makers Dr Reddy's Laboratories, Cipla, Emcure Pharmaceuticals, Sun Pharmaceutical Industries and Torrent Pharmaceuticals have decided to collaborate for clinical trial of the investigational oral antiviral drug Molnupiravir for the treatment of mild Covid-19.
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in the country, according to regulatory filings by Dr Reddy's and Cipla. As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation, Dr Reddy's will conduct the clinical trial using its product, and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr Reddy's in its clinical trial, the filings noted.
The clinical trial will be conducted for the treatment of mild Covid-19 in an outpatient setting and is expected to take place between June and September across India with the recruitment of 1,200 patients, they added. Such collaboration for a clinical trial is a first of its kind within the Indian pharma industry and will aim to investigate yet another line of treatment in the collective fight against the Covid-19 pandemic, the companies noted.
On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply Molnupiravir for the treatment of Covid-19 in India, it added. Molnupiravir is an oral antiviral drug that inhibits the replication of multiple RNA viruses including SARS-CoV-2. It is currently being studied by MSD, through a collaboration with Ridgeback Biotherapeutics, in a Phase Ill trial for the treatment of non-hospitalised patients with confirmed Covid-19 globally.
Between March and April this year, the five Indian pharma companies had individually entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low- and middle-income countries.
